文献速递瓣膜外科

类癌心脏病瓣膜替换术预后改善分析

Improving outcome of valve replacement for carcinoid heart disease.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-10-03

该研究回顾了1985年至2018年在Mayo Clinic接受类癌心脏病手术的240例成人患者,分析临床和超声变量与早期死亡率和晚期生存的关系。早期死亡率从1985-1994年的29%降至2005年后的5%,总体1、3、5年生存率分别为69%、48%、34%。高龄、晚期NYHA分级和肌酐非线性效应与总体死亡率独立相关。

要点

  • 类癌心脏病瓣膜替换术早期死亡率已降至5%。
  • 高龄、晚期NYHA分级和肌酐非线性效应预测总体死亡。
  • 早期干预可能改善总体生存率。

核心结论

  • 类癌心脏病瓣膜替换术短期死亡率可接受,当前时代早期风险已降低。
  • 早期干预可能改善总体生存率。

研究设计与样本

  • 回顾性队列研究,纳入1985年11月至2018年1月在Mayo Clinic接受类癌心脏病手术的240例成人患者。
  • 分析多个临床和超声心动图变量与早期死亡率和晚期生存的关联。

主要发现

  • 患者中位年龄63岁(IQR 55-69),男性117例(49%)。
  • 术前157例(70%)为NYHA III或IV级。
  • 早期死亡率:1985-1994年为29%(9/22),1995-2004年为7%(6/81),2005年后为5%(7/128)。
  • 总体1年、3年、5年生存率估计分别为69%、48%、34%。
  • 高龄、晚期NYHA分级和肌酐非线性效应与总体死亡率独立相关。

临床怎么用

  • 对于类癌心脏病患者,瓣膜替换术可考虑,当前早期风险较低。
  • 关注高龄、NYHA分级高和肌酐异常患者,可能需更积极管理。
  • 早期干预可能改善生存,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Carcinoid heart disease is characterized by tricuspid valve regurgitation and varying degrees of pulmonary valve regurgitation or stenosis. Valve replacement procedures may be complicated by systemic effects of carcinoid syndrome, as well as hepatic dysfunction and right heart failure. This study was performed to identify factors that might be associated with improving early mortality rates and late outcomes. METHODS: Between November 1985 and January 2018, 240 adult patients underwent surgery for carcinoid heart disease at the Mayo Clinic. We analyzed the association of multiple clinical and echocardiographic variables on early mortality and late survival. RESULTS: The median (interquartile range) age of patients was 63 years (55-69), and 117 patients (49%) were male. Before operation, 157 patients (70%) had New York Heart Association class III or IV limitation. Somatostatin analogs were used in 221 patients (92%), and long-acting somatostatins were used in 130 patients (54%). Loop diuretic therapy was used preoperatively in 125 patients (52%). Early mortality rate was 29% (9/22) between 1985 and 1994, but decreased to 7% (6/81) during 1995 to 2004, and to 5% (7/128) from 2005 onward. Overall survival estimates at 1, 3, and 5 years were 69%, 48%, and 34%, respectively. Older age, advanced New York Heart Association class, and a nonlinear effect of creatinine were independently associated with overall mortality. CONCLUSIONS: Valve replacement for carcinoid heart disease has acceptable short-term mortality, and early risk has decreased in the current era. Earlier intervention may improve overall survival.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nguyen A, Schaff HV, Abel MD, et al. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg. 2018. PMID: 30527716. doi:10.1016/j.jtcvs.2018.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。